Abstract
In laboratory mice, pituitary dwarfism caused by genetic reduction or elimination of the activity of growth hormone (GH) significantly extends lifespan. The effects of congenital pituitary dwarfism on human longevity are not well documented. To analyse the effects of untreated pituitary dwarfism on human lifespan, the longevity of a diverse group of widely known little people, the 124 adults who played “Munchkins” in the 1939 movie The Wizard of Oz was investigated. Survival of “Munchkin” actors with those of controls defined as cast members of The Wizard of Oz and those of other contemporary Academy Award winning Hollywood movies was compared. According to the Kaplan–Meier survival curves, survival of female and male “Munchkin” actors was shorter than cast controls and Hollywood controls of respective sexes. Cox regression analyses showed that female “Munchkin” actors had significantly higher risk ratios compared to both female cast controls (RR, 1.70; 95% CI, 1.05 to 2.77) and female Hollywood controls (RR, 1.52; 95% CI, 1.03 to 2.24). Similar trends were also discernible for men, albeit point estimates were not significant. The lack of lifespan extension in “Munchkin” actors does not support the hypothesis that hereditary GH deficiency regulates longevity in humans.
Keywords: Munchkin, Dwarfism, The Wizard of Oz
Introduction
The most reliable and effective genetic intervention to lengthen the life of laboratory mice is to reduce or eliminate the activity of pituitary growth hormone (GH). Long-lived mouse pituitary dwarfs have been created by spontaneous mutations in genes for the transcription factors, Prop1 or Pit1, both of which abolish the development of pituitary GH-, prolactin-, and thyroid stimulating hormone–producing cells, by a spontaneous mutation in the growth hormone releasing hormone (GHRH) receptor, inhibiting GH release by the pituitary or by targeted disruption of GHRH or the GH receptor [1, 2]. These interventions extend life in both sexes and have been replicated in multiple labs across multiple mouse genotypes. In addition, outbred mice artificially selected for diverse early life growth trajectories displayed a negative correlation between body weight at age 6 months and longevity [3]. By contrast, genetically GH-deficient Lewis rats did not exhibit extended longevity unless GH was administered for 10 weeks in early life [4]. These robust findings in mice and their apparent contradiction in rats raise the question: Which paradigm represents the human impact of reduced GH activity?
Congenital pituitary dwarfism is well-known in humans. Typically, cases are classified as either isolated GH deficiency, due to mutations in GH- or GHRH-producing genes or their receptors or multiple pituitary hormone deficiency, due to mutations in developmental transcription factor genes such as Prop1 or Pou1F1 (human version of mouse Pit1), which affect multiple pituitary hormones [5]. Despite the large number of individuals affected by these mutations, their longevity impact has been difficult to assess due to the development of therapeutic hormone replacement in the 1960s. What evidence is at hand is mixed. A Swiss cohort with a disabling GH mutation in the nineteenth and early twentieth centuries had reduced longevity compared with unaffected siblings and unrelated contemporaries [6]. Israeli and Ecuadorian populations with GH receptor mutations did not differ in longevity from contemporaries, although they did exhibit lower incidences of cancer and diabetes [7, 8]. However, earlier study of the same Ecuadorian population found higher mortality before age 7 in dwarfs compared with normal size siblings [9]. There was also no significant longevity difference in a Brazilian cohort with a GHRH receptor mutation, although that population also exhibited reductions in a number of cancer types [10]. In a Croatian population with a disabling mutation in the Prop1 gene, twenty-three untreated heredity dwarfs have been historically identified. Longevity information, however, is only available for nine untreated individuals, including four siblings born in the late nineteenth century. Of those siblings, the two brothers died at 68 and 77 years of age, fairly typical for that population, but the two sisters lived to 87 and 91 years, provocatively longer than average for contemporary women [11].
Given the sparse information on the longevity of untreated pituitary dwarfs, we have investigated the longevity of a diverse group of widely known little people, the 124 adults who played “Munchkins” in the 1939 movie, The Wizard of Oz. Actors for “Munchkin” roles were recruited by professional agents who scoured the country looking for, in the words of producer Mervyn LeRoy, “little people who were little and cute and looked perfect” [12]. That is, they needed to be small but appropriately proportioned. Headhunters were instructed to weed out achondroplastic dwarfs with their disproportionately short arms and legs. Consequently, only five of the Munchkins were achondroplastic dwarfs, and we have deleted them from the following analysis. Therefore, although we do not know the genetic basis of their reduced size, it almost certain signals profoundly reduced GH activity. Median height from a sample of twenty-three known-height “Munchkin” actors was 102 cm, considerably shorter than most of the known genetic hypopituitary dwarfs. For instance, males in the Brazilian cohort with Isolated Growth Hormone Deficiency averaged 129 cm in height and females 117 cm; the Croatian Prop1 cluster had mean height of 125 cm.
Most “Munchkin” actors were recruited from circus and carnival acts, from vaudeville shows, or from a variety of performance venues. They largely came from impoverished, often nightmarish backgrounds, and in some cases had been sold by their parents to passing carnival impresarios. Many had immigrated from Europe, where “little people troupes” were particularly popular in the early part of the twentieth century. They often changed names and possibly birth dates in doing so. Also, as performers who shifted often from job to job, they regularly took on new stage names. All this makes establishing birth year challenging, and for most of the “Munchkin” actors, we accepted their self-stated birth year unless other information was available. Ironically, their lot did not improve dramatically while acting in The Wizard of Oz, during which as one of them remarked, they were paid less than Toto, the dog. Individual death years were gathered from multiple sources and confirmed with local obituaries whenever possible. In total, we validated age-at-death for 88 little people actors. At the time the movie was filmed, their median age was 32 years, the youngest being 11 years old at the time and the oldest 69 years. We compared survival of “Munchkin” actors with those of controls defined as cast members of The Wizard of Oz and those of other contemporary Academy Award winning Hollywood movies.
Methods
Study population and analysis of lifespan data
Data of actors from the movie The Wizard of Oz (1939) are publicly available (Fig. 1). Cases were defined as actors playing Munchkin roles. Only participants with available date of birth and death were included in the study. As for controls, two sets were selected: cast controls and Hollywood controls. Cast controls were defined as other cast members of The Wizard of Oz movie paired to cases according to sex at a ratio of 1:1. Hollywood controls on the other hand were defined as cast member of movies that won an Academy Award between 1938 and 1940. We decided to include movies from 1938 to 1940 as the production of The Wizard of Oz began in 1938 thanks to the success of Snow White and the Seven Dwarf after which filmmaker realized that the adaptation of fairy tales and children’s stories can be popular [13]. The movie The Wizard of Oz was eventually released in 1939 and was awarded an Academy Award for Best Original Music Score in 1940 [14]. Movies from which controls were selected are displayed in Table 1. Hollywood controls were paired to cases according to sex and age at release date of The Wizard of Oz (1939) at a 1:3 ratio. Age was matched by conducting age group matching using the following age groups: 10–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, and ≥ 50.
Table 1.
Movie | Award | Year |
---|---|---|
The Adventures of Robin Hood | Best Art Direction, Best Film Editing, Best Original Music Score | 1938 |
The Great Waltz | Best Cinematography | 1938 |
You Can’t Take It with You | Best Picture, Best Director | 1938 |
Jezebel | Best Actress in a Leading Role, Best Actress in a Supporting Role | 1938 |
Snow White and the Seven Dwarfs | Best Music Score/Honorary Award | 1938/1939 |
Gone with the Wind | Best Picture, Best Director, Best Actress in a Leading Role, Best Actress in a Supporting Role, Best Screenplay Writing, Best Colour Cinematography, Best Art Direction, Best Screenplay Writing | 1939 |
Wuthering Heights | Best Black-and-White Cinematography | 1939 |
Stagecoach | Best Actress in a Supporting Role, Best Music Score | 1939 |
Goodbye, Mr. Chips | Best Actor in a Leading Role | 1939 |
Sons of Liberty | Best Short Subject (Two-reel) | 1939 |
When Tomorrow Comes | Best Sound Recording | 1939 |
Busy Little Bears | Best Short Subject (One-reel) | 1940 |
Mr. Smith Goes to Washington | Best Writing, Original Story | 1940 |
Ugly Duckling | Best Short Subject (Cartoons) | 1940 |
The Rains Came | Best Special Effects | 1940 |
To examine the survival of participants, Kaplan–Meier survival curves were plotted, and Cox regression analyses were conducted with follow-up time and total lifespan as underlying time factor comparing “Munchkin” actors to cast controls and Hollywood controls in separate analyses. Outcome was defined as death as a dichotomous variable. Follow-up time was defined as the time between 1939 and death of participants (or 2022 if participants were alive at the time of the present analysis), whereas lifespan was defined as the total number of years lived using the same endpoints. Additionally, Gompertz mortality models were also performed to compare the differences in the age-related changes of age-specific mortality between groups [15]. Each analysis was conducted separately by sex as well. All statistics were carried out with STATA 15 and SPSS 28.0.0. Significance was set at p < 0.05.
Results
We were able to collect year of birth and death for 98 of them. A total of 9 participants were excluded because either a reliable birth or death year was unavailable. Four participants were excluded because they suffered from achondroplasia and not pituitary dwarfism, resulting in a total of 85 (n = 50 male, n = 35 female) “Munchkin” actors included in the present analysis.
“Munchkin” actors had similar follow-up times, but shorter total lifespan as opposed to both cast controls and Hollywood controls (Table 2). This is also supported by the Kaplan–Meier survival curves, which show a lower survival for “Munchkin” actors compared to both cast controls and Hollywood controls (Fig. 2A and 3A). Cox regression analyses with follow-up time as underlying time variable showed significantly higher risk ratios for “Munchkin” actors when compared to cast controls [risk ratios (RR), 1.39; 95% confidence interval (95% CI), 1.01–1.91] and a non-significantly higher point estimate when using Hollywood controls as reference (Fig. 2B and 3B). Similar trends were also observed for Cox regression models with total lifespan as underlying time variable, albeit risk ratios were not significant when compared to cast controls and Hollywood controls (Fig. 2C and 3C). The Gompertz plots showed a significantly steeper increase of age-specific mortality for cast controls (p = 0.018), whereas there were no significant differences when using Hollywood controls as reference (Fig. 2D and 3D).
Table 2.
Age at shooting | Follow-up time | Total lifespan | |
---|---|---|---|
Median (IQR) | Median (IQR) | Median (IQR) | |
“Munchkin” actors | |||
Female (n = 35) | 33.0 (23.0–39.0) | 41.0 (30.0–56.0) | 75.0 (63.0–84.0) |
Male (n = 50) | 30.0 (22.0–37.0) | 41.0 (20.8–54.5) | 73.0 (56.5–84.0) |
Total (n = 85) | 31.0 (22.0–37.5) | 41.0 (26.5–55.5) | 74.0 (60.5–83.5) |
Cast controls | |||
Female (n = 35) | 31.0 (22.0–38.0) | 52.0 (33.0–63.0) | 83.0 (76.0–86.0) |
Male (n = 50) | 41.0 (35.8–49.3) | 30.0 (17.0–46.0) | 78.5 (64.0–86.0) |
Total (n = 85) | 37.0 (30.5–47.0) | 39.0 (23.5–54.5) | 81.0 (69.0–86.0) |
Hollywood controls | |||
Female (n = 105) | 32.0 (23.0–38.0) | 48.0 (33.0–57.5) | 81.0 (69.0–90.0) |
Male (n = 150) | 31.0 (22.8–38.0 | 41.5 (28.0–61.3) | 75.0 (65.0–86.0) |
Total (n = 255) | 31.0 (23.0–38.0) | 45.0 (30.0–58.0) | 78.0 (67.0–87.0) |
Abbreviation: IQR, interquartile range
When participants were analysed separately by sex, female cast controls and female Hollywood controls had longer follow-up times and total lifespans than “Munchkin” actors. Among men, cast controls had shorter follow-up time (due to their higher age at the time of shooting), but longer lifespan. Male Hollywood controls exhibited a similar follow-up time and lifespan compared to male “Munchkin” actors (Table 2). According to the Kaplan–Meier survival curves, survival of female and male “Munchkin” actors was mostly shorter than cast controls and Hollywood controls of respective sexes (Fig. 4A, 5, 6 and 7A). When using follow-up time as underlying time variable in the Cox regression analyses, female “Munchkin” actors had significantly higher risk ratios compared to both female cast controls (RR, 1.70; 95% CI, 1.05–2.77) and female Hollywood controls (RR, 1.52; 95% CI, 1.03–2.24). Similar results were also discernible for men, albeit point estimates were not significant (Fig. 4B-C567B-C). The Gompertz plots revealed a significantly steeper increase of age-specific mortality for male cast controls compared to male “Munchkin” actors (p < 0.001) and a non-significant difference between female groups (Fig. 4D-5D, respectively). Conversely, the Gompertz plots using Hollywood controls as reference showed non-significant differences between males and a significantly steeper incline for female “Munchkin” actors (p < 0.001; due the outlier last datapoint) (Fig. 6D-7D, respectively) (Table 3).
Table 3.
“Munchkin” actors vs. cast controls | “Munchkin” actors vs. Hollywood controls | |||
---|---|---|---|---|
Follow-up time* | Lifespan* | Follow-up time* | Lifespan* | |
aRR (95% CI) | aRR (95% CI) | aRR (95% CI) | aRR (95% CI) | |
Female | 1.70 (1.05–2.77)* | 1.64 (1.01–2.67)* | 1.52 (1.03–2.24)* | 1.47 (1.00–2.17)* |
Male | 1.14 (0.74–1.74) | 1.12 (0.73–1.70) | 1.05 (0.76–1.45) | 1.05 (0.76–1.45) |
Total | 1.39 (1.01–1.91)* | 1.34 (0.98–1.85) | 1.24 (0.97–1.59) | 1.23 (0.96–1.57) |
Age at shooting | 1.09 (1.07–1.10)* | 1.01 (1.00–1.02) | 1.10 (1.09–1.12)* | 1.03 (1.02–1.04)* |
Abbreviations: aRR, adjusted risk ratio; IQR, interquartile range
*Follow-up of subjects began from their age at shooting and ended with their death. Cast controls were chosen as reference. Risk ratios were adjusted for age at shooting, sex and disease status by sex interaction
Discussion
The key finding of this study is that “Munchkin” actors may have lower survival rates than healthy controls. Our data also suggests that lower survival may be more prominent among female “Munchkin” actors. This latter observation was consistent across different Cox proportional regression models. Similar trends were also discernible for male “Munchkin” actors; however, the difference did not reach statistical significance. Gompertz models revealed some inconsistencies for the change in age-specific mortality between comparison groups, but the Gompertz plots with stronger statistical power comprised of participants matched for age and sex at a ratio of 1:3 corroborate the results concerning the sex differences observed in the Cox proportional regression models.
Many disorders can cause short stature, including GH/IGF-1 deficiency, resistance to GH, thyroid hormone deficiency, achondroplasia, malnutrition and others. GH/IGF-1 deficiency and resistance to GH are characterized by proportionate short stature, whereas many genetic skeletal dysplasias are known for disproportionate short stature. The appearance of “Munchkin” actors on the film suggests that most of them had proportionate short stature, likely due to GH/IGF-1 deficiency. In fact, several “Munchkin” actors were known to have been diagnosed with pituitary dwarfism. Examples for “Munchkin” actors with proportionate short stature include Jerry Maren (born Gerard Marenghi; 1920–2018; diagnosed with GH-responsive pituitary dwarfism; Fig. 1), Jakob Gerlich (born Leo Fuks; 1925–1960) and Harry Earles (1902–1985; diagnosed with pituitary dwarfism), who played the Munchkin members of the Lollipop Guild [16]; Mickey Carroll (1920–2009, diagnosed with pituitary dwarfism), who played the Town Crier; and Olga C. Nardone (1921–2010), who played a member of the Lullaby League. Notably, none of the “Munchkin” actors with diagnosed pituitary dwarfism outlived the longest-lived cast controls. The few “Munchkin” actors who had short-limb short stature, which is known to be caused by achondroplasia, hypochondroplasia, pseudoachondroplasia or multiple epiphyseal dysplasia, were excluded from the analysis.
Our findings accord with the conclusions of previous studies investigating the effects of hereditary GH deficient dwarfism on lifespan [17]. Accordingly, in untreated subjects exhibiting isolated GH deficiency due to a deletion of genomic DNA encompassing the GH-1 gene, median life span is significantly shorter than that of unaffected brothers and sisters [males, 56 vs. 75 years (p < 0.0001); females, 46 vs. 80 years (p < 0.0001)]17. Lifespan in patients with congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene was also reported to be shorter than the general population [18]. Patients with childhood-onset isolated GH deficiency also exhibit a number of health problems and have poor quality of life [19–21]. The finding that disruption of GH/IGF-1 signalling does not extend human lifespan is also supported by survival data obtained in a cohort of rural Ecuadorian individuals with Laron syndrome [22]. These patients carry mutations in the growth hormone receptor (GHR) gene that lead to resistance to GH and consequential severe IGF-1 deficiency. Similar findings were reported in an Israeli cohort of patients with Laron dwarfism [8]. Of note, the murine model of the Laron syndrome (GHR/BP −/− Laron mice) [23] has a longer life expectancy than wild-type controls [24], highlighting the critical differences between the roles of the GH/IGF-1 axis in regulation of longevity in humans and laboratory animals including mice..
GH and IGF-1 confer multifaceted cytoprotective, growth-promoting and anti-aging effects [25–51]. In addition to short stature, early-onset disruption of GH/IGF-1 signalling compromise health in a myriad of ways. For example, patients with Laron syndrome have poor quality of life, exhibiting cognitive and psychological problems, small genitalia, birth defects, ophthalmological problems, obesity, hyperlipidaemia, fatty liver, sleep problems, acromicria, small brain size and cerebrovascular disease [8, 22]. GH/IGF-1 deficiency increases cardiovascular risk [52] and risk for diabetes mellitus [20]. GH replacement therapy in adults with hypopituitary GH deficiency leads to a sustained improvement of adverse serum lipid profile and body composition [20]. The main exception by which disruption of GH/IGF-1 signalling may act to prevent the development of a specific age-related disease is its anti-cancer effect. Epidemiological studies confirm that similar to the findings observed in animal models of early-onset GH/IGF-I deficiency [53–59], patients with congenital GH/IGF-I deficiency have a significantly reduced risk of cancer development [8, 22, 60, 61]. In mice, in which malignancies are a leading cause of death, disruption of GH/IGF-I signalling extends lifespan primarily by inhibiting development of cancer [56, 58, 62–65]. In humans, the deleterious effects of attenuation/disruption of GH/IGF-I signalling on the cardiovascular system and the central nervous system likely overshadow its inhibitory effects on the pathogenesis of malignant diseases [66–68], and thus its net effect may actually shorten lifespan. This is supported by a study performed on humans carrying mutations of the growth hormone receptor gene in which participants seemed to be protected from cancers, while there was an increased cardiac disease risk as a cause of death among these participants [22].
Interestingly, when stratified by sex, the difference between the lifespan of “Munchkin” actors and cast controls persisted only in females, similar to the findings in patients with congenital GH deficiency [18]. Previous preclinical, translational and epidemiological studies demonstrate clear sexually dimorphic actions of the GH/IGF-1 axis [18, 53, 67, 69]. The existing evidence suggest that in mice, the sexually dimorphic effects of disruption of GH/IGF-1 signalling on lifespan are due to the sex differences in its anti-cancer actions [53]. In humans the mechanisms contributing to the sexually dimorphic effects of the GH/IGF-1 axis are not well understood and warrant additional studies.
Finally, we must address certain limitations as well, most importantly the lack of information on confounding factors. The socioeconomic status, such as salary and living conditions of “Munchkin” actors, a marginalized group within the population, may be lower than that of actors not affected by this ailment. Other factors that may have biased our results are the possible stigmatization of individuals affected by dwarfism by the general population, which may have predisposed these individuals to riskier behaviours for instance. Judy Garland, who played Dorothy in the film, complained about the drinking problem of “Munchkin” actors in a 1967 interview. Yet, we do not have detailed information whether or not they actually exhibited riskier health behaviour, such as smoking and excessive alcohol consumption more often than members of the control groups. Since these factors may influence mortality, studies examining the longevity of human dwarf cohorts should adjust for their effect for a more precise estimation of differences in mortality between groups.
Author contribution
Vince Fazekas-Pongor: formal analysis, writing-review and editing, data visualization, performed literature search. Anna Péterfi: formal analysis, writing-review and editing. Zsófia Szarvas: formal analysis, writing-review and editing. Norbert Dosa: formal analysis, writing-review and editing. Monika Fekete: formal analysis, writing-review and editing. Adam G. Tabak: formal analysis, writing-review and editing, supervision. Anna Csiszar: conceptualization, writing-review and editing. William E. Sonntag: writing-review and editing. Steven N. Austad: conceptualization, writing-original draft, performed literature search. Zoltan Ungvari: original idea for the study, conceptualization, writing-original draft, performed literature search, supervision.
Funding
The authors of this manuscript were supported by grants from the National Institute on Aging (RF1AG072295, R01AG055395, R01AG068295; R01AG070915, K01AG073614), the National Institute of Neurological Disorders and Stroke (R01NS100782), the National Cancer Institute (R01CA255840), the Presbyterian Health Foundation, the Reynolds Foundation, the Oklahoma Nathan Shock Center (P30AG050911) and the Cellular and Molecular GeroScience CoBRE (P20GM125528). AGT, VP, ZSSZ and AP were supported by TKP2021-NKTA-47 and RRF-2.3.1–21-2022–00003 provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the 2021 Thematic Excellence Programme funding scheme.
Declarations
Competing interests
Dr. Anna Csiszar serves as Associate Editor for The Journal of Gerontology, Series A: Biological Sciences and Medical Sciences and GeroScience. Dr. Zoltan Ungvari serves as Editor-in-Chief for GeroScience and as Consulting Editor for The American Journal of Physiology-Heart and Circulatory Physiology. Dr. William E. Sonntag, Dr. Stefano Tarantini and Dr. Andriy Yabluchanskiy serve as Associate Editors for GeroScience.
Disclaimer
The funding sources had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Vince Fazekas-Pongor and Anna Péterfi contributed in this work.
References
- 1.Bartke A. Minireview: role of the growth hormone/insulin-like growth factor system in mammalian aging. Endocrinol. 2005;146:3718–3723. doi: 10.1210/en.2005-0411. [DOI] [PubMed] [Google Scholar]
- 2.Sun LY, Spong A, Swindell WR, Fang Y, Hill C, Huber JA, Boehm JD, Westbrook R, Salvatori R, Bartke A. Growth hormone-releasing hormone disruption extends lifespan and regulates response to caloric restriction in mice. eLife. 2013;2:e01098. doi: 10.7554/eLife.01098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Miller RA, Chrisp C, Atchley W. Differential longevity in mouse stocks selected for early life growth trajectory. JGerontolA BiolSciMedSci. 2000;55:B455–B461. doi: 10.1093/gerona/55.9.b455. [DOI] [PubMed] [Google Scholar]
- 4.Sonntag WE, Carter CS, Ikeno Y, Ekenstedt K, Carlson CS, Loeser RF, Chakrabarty S, Lee S, Bennett C, Ingram R, Moore T, Ramsey M. Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinol. 2005;146:2920–2932. doi: 10.1210/en.2005-0058. [DOI] [PubMed] [Google Scholar]
- 5.Laron Z. Do deficiencies in growth hormone and insulin-like growth factor-1 (IGF-1) shorten or prolong longevity? Mech Ageing Dev. 2005;126:305–307. doi: 10.1016/j.mad.2004.08.022. [DOI] [PubMed] [Google Scholar]
- 6.Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003;88:3664–3667. doi: 10.1210/jc.2002-021938. [DOI] [PubMed] [Google Scholar]
- 7.Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, De CR, Cohen P, Longo VD. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling cancer and diabetes in humans. Sci Transl Med. 2011;3:70ra13. doi: 10.1126/scitranslmed.3001845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Laron Z, Kauli R, Lapkina L, Werner H. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome. Mutat Res Rev Mutat Res. 2017;772:123–133. doi: 10.1016/j.mrrev.2016.08.002. [DOI] [PubMed] [Google Scholar]
- 9.Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke U. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab. 1999;84:4436–4443. doi: 10.1210/jcem.84.12.6283. [DOI] [PubMed] [Google Scholar]
- 10.Aguiar-Oliveira MH, Bartke A. Growth hormone deficiency: health and longevity. Endocr Rev. 2019;40:575–601. doi: 10.1210/er.2018-00216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Krzisnik C, Grguric S, Cvijovic M, Laron Z. Longevity of the hypopituitary patients from the island of Krk: a follow-up study. Pediatr Endocrinol Rev. 2010;7:357–362. [PubMed] [Google Scholar]
- 12.Weinstock M. “The Wizard of Oz,” the last munchkin, and the little people left behind. New Yorker. 2018. https://www.newyorker.com/culture/culture-desk/the-wizard-of-oz-the-last-munchkin-and-the-little-people-left-behind. Accessed 02/11/2022.
- 13.Harmetz A. The making of The Wizard of Oz. New York City: Hyperion; 2004.
- 14.Kuchan MJ, Jo H, Frangos JA. Role of G proteins in shear stress-mediated nitric oxide production by endothelial cells. Am J Physiol. 1994;267:C753–C758. doi: 10.1152/ajpcell.1994.267.3.C753. [DOI] [PubMed] [Google Scholar]
- 15.de Magalhães JP, Cabral JAS, Magalhães D. The influence of genes on the aging process of mice: a statistical assessment of the genetics of aging. Genetics. 2005;169:265–274. doi: 10.1534/genetics.104.032292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Jerry Maren, who sang and danced as a munchkin in Oz, dies at 98. NYTimes.com. June 6, 2018. https://www.nytimes.com/2018/06/06/arts/jerry-maren-dead-wizard-of-oz-munchkin.html. Accessed 05/03/2022.
- 17.Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab. 2003;88:3664–3667. doi: 10.1210/jc.2002-021938. [DOI] [PubMed] [Google Scholar]
- 18.Aguiar-Oliveira MH, Oliveira FT, Pereira RM, Oliveira CR, Blackford A, Valenca EH, Santos EG, Gois-Junior MB, Meneguz-Moreno RA, Araujo VP, Oliveira-Neto LA, Almeida RP, Santos MA, Farias NT, Silveira DC, Cabral GW, Calazans FR, Seabra JD, Lopes TF, Rodrigues EO, Porto LA, Oliveira IP, Melo EV, Martari M, Salvatori R. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J Clin Endocrinol Metab. 2010;95:714–721. doi: 10.1210/jc.2009-1879. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.R Abs AF Mattsson AB Bengtsson U Feldt-Rasmussen MI Goth M Koltowska-Haggstrom JP Monson J Verhelst P Wilton and Group KS Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients A sub-analysis of the KIMS database. Growth Horm IGF Res. 2005;15:349–59. doi: 10.1016/j.ghir.2005.06.018. [DOI] [PubMed] [Google Scholar]
- 20.Abs R, Mattsson AF, Thunander M, Verhelst J, Goth MI, Wilton P, Koltowska-Haggstrom M, Luger A. Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol. 2013;168:297–305. doi: 10.1530/EJE-12-0807. [DOI] [PubMed] [Google Scholar]
- 21.Gaillard RC, Mattsson AF, Akerblad AC, Bengtsson BA, Cara J, Feldt-Rasmussen U, Koltowska-Haggstrom M, Monson JP, Saller B, Wilton P, Abs R. Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol. 2012;166:1069–1077. doi: 10.1530/EJE-11-1028. [DOI] [PubMed] [Google Scholar]
- 22.Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling cancer and diabetes in humans. Sci Transl Med. 2011;3:70ra13. doi: 10.1126/scitranslmed.3001845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse) Proc Natl Acad Sci U S A. 1997;94:13215–13220. doi: 10.1073/pnas.94.24.13215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinol. 2000;141:2608–2613. doi: 10.1210/endo.141.7.7586. [DOI] [PubMed] [Google Scholar]
- 25.Ashpole NM, Herron JC, Estep PN, Logan S, Hodges EL, Yabluchanskiy A, Humphrey MB, Sonntag WE. Differential effects of IGF-1 deficiency during the life span on structural and biomechanical properties in the tibia of aged mice. Age (Dordr) 2016;38:38. doi: 10.1007/s11357-016-9902-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ashpole NM, Herron JC, Mitschelen MC, Farley JA, Logan S, Yan H, Ungvari Z, Hodges EL, Csiszar A, Ikeno Y, Humphrey MB and Sonntag WE. IGF-1 regulates vertebral bone aging through sex-specific and time-dependent mechanisms. J Bone Miner Res. 2015;31(2):443–54. [DOI] [PMC free article] [PubMed]
- 27.Bailey-Downs LC, Mitschelen M, Sosnowska D, Toth P, Pinto JT, Ballabh P, Valcarcel-Ares MN, Farley J, Koller A, Henthorn JC, Bass C, Sonntag WE, Ungvari Z, Csiszar A. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci. 2012;67:313–329. doi: 10.1093/gerona/glr164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Bailey-Downs LC, Sosnowska D, Toth P, Mitschelen M, Gautam T, Henthorn JC, Ballabh P, Koller A, Farley JA, Sonntag WE, Csiszar A, Ungvari Z. Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J Gerontol A Biol Sci Med Sci. 2012;67:553–564. doi: 10.1093/gerona/glr197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.D'Costa AP, Xu X, Ingram RL, Sonntag WE. Insulin-like growth factor-1 stimulation of protein synthesis is attenuated in cerebral cortex of aging rats. Neurosci. 1995;65:805–813. doi: 10.1016/0306-4522(94)00495-Q. [DOI] [PubMed] [Google Scholar]
- 30.Deak F, Sonntag WE. Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1. J Gerontol A Biol Sci Med Sci. 2012;67:611–625. doi: 10.1093/gerona/gls118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Farias Quipildor GE, Mao K, Hu Z, Novaj A, Cui MH, Gulinello M, Branch CA, Gubbi S, Patel K, Moellering DR, Tarantini S, Kiss T, Yabluchanskiy A, Ungvari Z, Sonntag WE, Huffman DM. Central IGF-1 protects against features of cognitive and sensorimotor decline with aging in male mice. Gerosci. 2019;41:185–208. doi: 10.1007/s11357-019-00065-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Grill JD, Sonntag WE, Riddle DR. Dendritic stability in a model of adult-onset IGF-I deficiency. Growth Horm IGF Res. 2005;15:337–348. doi: 10.1016/j.ghir.2005.07.002. [DOI] [PubMed] [Google Scholar]
- 33.Groban L, Lin M, Kassik KA, Ingram RL, Sonntag WE. Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation. Growth Horm IGF Res. 2011;21:81–88. doi: 10.1016/j.ghir.2011.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hua K, Forbes ME, Lichtenwalner RJ, Sonntag WE, Riddle DR. Adult-onset deficiency in growth hormone and insulin-like growth factor-I alters oligodendrocyte turnover in the corpus callosum. Glia. 2009;57:1062–1071. doi: 10.1002/glia.20829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Khan AS, Lynch CD, Sane DC, Willingham MC, Sonntag WE. Growth hormone increases regional coronary blood flow and capillary density in aged rats. J Gerontol A Biol Sci Med Sci. 2001;56:B364–B371. doi: 10.1093/gerona/56.8.B364. [DOI] [PubMed] [Google Scholar]
- 36.Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neurosci. 2001;107:603–613. doi: 10.1016/S0306-4522(01)00378-5. [DOI] [PubMed] [Google Scholar]
- 37.Lichtenwalner RJ, Forbes ME, Sonntag WE, Riddle DR. Adult-onset deficiency in growth hormone and insulin-like growth factor-I decreases survival of dentate granule neurons: insights into the regulation of adult hippocampal neurogenesis. J Neurosci Res. 2006;83:199–210. doi: 10.1002/jnr.20719. [DOI] [PubMed] [Google Scholar]
- 38.Logan S, Pharaoh GA, Marlin MC, Masser DR, Matsuzaki S, Wronowski B, Yeganeh A, Parks EE, Premkumar P, Farley JA, Owen DB, Humphries KM, Kinter M, Freeman WM, Szweda LI, Van Remmen H, Sonntag WE. Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-beta uptake in astrocytes. Mol Metab. 2018;9:141–155. doi: 10.1016/j.molmet.2018.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Miller LR, Tarantini S, Nyul-Toth A, Johnston MP, Martin T, Bullen EC, Bickel MA, Sonntag WE, Yabluchanskiy A, Csiszar A, Ungvari ZI, Elliott MH, Conley SM. Increased susceptibility to cerebral microhemorrhages is associated with imaging signs of microvascular degeneration in the retina in an insulin-like growth factor 1 deficient mouse model of accelerated aging. Front Aging Neurosci. 2022;14:788296. doi: 10.3389/fnagi.2022.788296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Mitschelen M, Yan H, Farley JA, Warrington JP, Han S, Herenu CB, Csiszar A, Ungvari Z, Bailey-Downs LC, Bass CE, Sonntag WE. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neurosci. 2011;185:50–60. doi: 10.1016/j.neuroscience.2011.04.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Nieves-Martinez E, Sonntag WE, Wilson A, Donahue A, Molina DP, Brunso-Bechtold J, Nicolle MM. Early-onset GH deficiency results in spatial memory impairment in mid-life and is prevented by GH supplementation. J Endocrinol. 2010;204:31–36. doi: 10.1677/JOE-09-0323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Poe BH, Linville C, Riddle DR, Sonntag WE, Brunso-Bechtold JK. Effects of age and insulin-like growth factor-1 on neuron and synapse numbers in area CA3 of hippocampus. Neurosci. 2001;107:231–238. doi: 10.1016/S0306-4522(01)00341-4. [DOI] [PubMed] [Google Scholar]
- 43.Ramsey MM, Weiner JL, Moore TP, Carter CS, Sonntag WE. Growth hormone treatment attenuates age-related changes in hippocampal short-term plasticity and spatial learning. Neurosci. 2004;129:119–127. doi: 10.1016/j.neuroscience.2004.08.001. [DOI] [PubMed] [Google Scholar]
- 44.Shi L, Linville MC, Tucker EW, Sonntag WE, Brunso-Bechtold JK. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cereb Cortex. 2005;15:571–577. doi: 10.1093/cercor/bhh158. [DOI] [PubMed] [Google Scholar]
- 45.Sonntag WE, Csiszar A, deCabo R, Ferrucci L, Ungvari Z. Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies. J Gerontol A Biol Sci Med Sci. 2012;67:587–598. doi: 10.1093/gerona/gls115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Sonntag WE, Deak F, Ashpole N, Toth P, Csiszar A, Freeman W, Ungvari Z. Insulin-like growth factor-1 in CNS and cerebrovascular aging. Front Aging Neurosci. 2013;5:27. doi: 10.3389/fnagi.2013.00027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Tarantini S, Balasubramanian P, Yabluchanskiy A, Ashpole NM, Logan S, Kiss T, Ungvari A, Nyul-Toth A, Schwartzman ML, Benyo Z, Sonntag WE, Csiszar A, Ungvari Z. IGF1R signaling regulates astrocyte-mediated neurovascular coupling in mice: implications for brain aging. Gerosci. 2021;43:901–911. doi: 10.1007/s11357-021-00350-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Tarantini S, Nyul-Toth A, Yabluchanskiy A, Csipo T, Mukli P, Balasubramanian P, Ungvari A, Toth P, Benyo Z, Sonntag WE, Ungvari Z, Csiszar A. Endothelial deficiency of insulin-like growth factor-1 receptor (IGF1R) impairs neurovascular coupling responses in mice, mimicking aspects of the brain aging phenotype. Gerosci. 2021;43:2387–2394. doi: 10.1007/s11357-021-00405-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, Springo Z, Fulop GA, Ashpole N, Gautam T, Giles CB, Wren JD, Sonntag WE, Csiszar A, Ungvari Z. Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. Aging Cell. 2017;16:469–479. doi: 10.1111/acel.12583. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Toth P, Tarantini S, Ashpole NM, Tucsek Z, Milne GL, Valcarcel-Ares NM, Menyhart A, Farkas E, Sonntag WE, Csiszar A, Ungvari Z. IGF-1 deficiency impairs neurovascular coupling in mice: implications for cerebromicrovascular aging. Aging Cell. 2015;14:1034–1044. doi: 10.1111/acel.12372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Toth P, Tucsek Z, Tarantini S, Sosnowska D, Gautam T, Mitschelen M, Koller A, Sonntag WE, Csiszar A, Ungvari Z. IGF-1 deficiency impairs cerebral myogenic autoregulation in hypertensive mice. J Cereb Blood Flow Metab. 2014;34:1887–1897. doi: 10.1038/jcbfm.2014.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P, Koltowska-Haggstrom M. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006;155:79–90. doi: 10.1530/eje.1.02179. [DOI] [PubMed] [Google Scholar]
- 53.Ashpole NM, Logan S, Yabluchanskiy A, Mitschelen MC, Yan H, Farley JA, Hodges EL, Ungvari Z, Csiszar A, Chen S, Georgescu C, Hubbard GB, Ikeno Y, Sonntag WE. IGF-1 has sexually dimorphic, pleiotropic, and time-dependent effects on healthspan, pathology, and lifespan. Geroscience. 2017;39:129–145. doi: 10.1007/s11357-017-9971-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Podlutsky A, Valcarcel-Ares MN, Yancey K, Podlutskaya V, Nagykaldi E, Gautam T, Miller RA, Sonntag WE, Csiszar A, Ungvari Z. The GH/IGF-1 axis in a critical period early in life determines cellular DNA repair capacity by altering transcriptional regulation of DNA repair-related genes: implications for the developmental origins of cancer. Gerosci. 2017;39:147–160. doi: 10.1007/s11357-017-9966-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Ramsey MM, Ingram RL, Cashion AB, Ng AH, Cline JM, Parlow AF, Sonntag WE. Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis. Endocrinol. 2002;143:4139–4142. doi: 10.1210/en.2002-220717. [DOI] [PubMed] [Google Scholar]
- 56.Garcia AM, Busuttil RA, Calder RB, Dolle ME, Diaz V, McMahan CA, Bartke A, Nelson J, Reddick R, Vijg J. Effect of Ames dwarfism and caloric restriction on spontaneous DNA mutation frequency in different mouse tissues. Mech Ageing Dev. 2008;129:528–533. doi: 10.1016/j.mad.2008.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Sun LY, Fang Y, Patki A, Koopman JJ, Allison DB, Hill CM, Masternak MM, Darcy J, Wang J, McFadden S and Bartke A. Longevity is impacted by growth hormone action during early postnatal period. Elife. 2017;6:e24059. [DOI] [PMC free article] [PubMed]
- 58.Ikeno Y, Bronson RT, Hubbard GB, Lee S, Bartke A. Delayed occurrence of fatal neoplastic diseases in ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci. 2003;58:291–296. doi: 10.1093/gerona/58.4.B291. [DOI] [PubMed] [Google Scholar]
- 59.Panici JA, Harper JM, Miller RA, Bartke A, Spong A, Masternak MM. Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice. FASEB J. 2010;24:1–7. doi: 10.1096/fj.10-163253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res. 2007;17:54–57. doi: 10.1016/j.ghir.2006.10.007. [DOI] [PubMed] [Google Scholar]
- 61.Steuerman R, Shevah O, Laron Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur J Endocrinol. 2011;164:485–489. doi: 10.1530/EJE-10-0859. [DOI] [PubMed] [Google Scholar]
- 62.Bartke A, Sun LY, Longo V. Somatotropic signaling: trade-offs between growth, reproductive development, and longevity. Physiol Rev. 2013;93:571–598. doi: 10.1152/physrev.00006.2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Gesing A, Wiesenborn D, Do A, Menon V, Schneider A, Victoria B, Stout MB, Kopchick JJ, Bartke A and Masternak MM. A Long-lived mouse lacking both growth hormone and growth hormone receptor: a new animal model for aging studies. J Gerontol A Biol Sci Med Sci. 2016;72(8):1054–1061. [DOI] [PMC free article] [PubMed]
- 64.Ikeno Y, Hubbard GB, Lee S, Cortez LA, Lew CM, Webb CR, Berryman DE, List EO, Kopchick JJ, Bartke A. Reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci. 2009;64:522–529. doi: 10.1093/gerona/glp017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Bartke A, Brown-Borg H. Life extension in the dwarf mouse. Curr Top Dev Biol. 2004;63:189–225. doi: 10.1016/S0070-2153(04)63006-7. [DOI] [PubMed] [Google Scholar]
- 66.Zhang WB, Ye K, Barzilai N, Milman S. The antagonistic pleiotropy of insulin-like growth factor 1. Aging Cell. 2021;20:e13443. doi: 10.1111/acel.13443. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Milman S, Atzmon G, Huffman DM, Wan J, Crandall JP, Cohen P, Barzilai N. Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014;13:769–771. doi: 10.1111/acel.12213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Zhang WB, Aleksic S, Gao T, Weiss EF, Demetriou E, Verghese J, Holtzer R, Barzilai N and Milman S. Insulin-like growth factor-1 and IGF binding proteins predict all-cause mortality and morbidity in older adults. Cells. 2020;9(6):1368. [DOI] [PMC free article] [PubMed]
- 69.Mao K, Quipildor GF, Tabrizian T, Novaj A, Guan F, Walters RO, Delahaye F, Hubbard GB, Ikeno Y, Ejima K, Li P, Allison DB, Salimi-Moosavi H, Beltran PJ, Cohen P, Barzilai N, Huffman DM. Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nat Commun. 2018;9:2394. doi: 10.1038/s41467-018-04805-5. [DOI] [PMC free article] [PubMed] [Google Scholar]